Skip to main content
Genix Pharmaceuticals Corporation logo

Genix Pharmaceuticals Corporation — Investor Relations & Filings

Ticker · GENX ISIN · CA37232A1093 LEI · 52990086O9FPM8QVNI53 TSXV Manufacturing
Open in API
Filings indexed 136 across all filing types
Latest filing 2025-06-18 Regulatory Filings
Country CA Canada
Listing TSXV GENX

About Genix Pharmaceuticals Corporation

https://genixpharm.com/

Genix Pharmaceuticals Corporation is an innovative life sciences company focused on the research, development, manufacturing, licensing, sales, and distribution of novel, branded, and generic products. The company operates as a formulator and marketer of life sciences-related products, specializing primarily in two key areas: nutraceuticals and ophthalmic solutions. Genix is committed to providing high-quality, affordable health solutions to patients through generic drugs, novel over-the-counter (OTC) products, and nutraceuticals. A core strategic focus is the prevention and management of chronic diseases, addressing conditions such as those associated with diabetes and hypertension.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 certification for interim filings (interim financial report and MD&A) by the CEO of a venture issuer under Canadian securities rules. It is not the interim report itself, but a regulatory certificate confirming review and accuracy. There is no specific category for certification forms, so it falls under the general “Regulatory Filings” fallback.
2025-06-18 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a certification (Form 52-109FV2) by the CFO for interim filings under NI 52-109. It is not the interim financial report or MD&A itself, nor is it an earnings release or a management commentary. It is a regulatory disclosure filing that does not fall under any of the specific categories (e.g., IR for interim report, ER for earnings release). Therefore, it is best classified under the general Regulatory Filings category.
2025-06-18 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled "Management’s Discussion and Analysis for the Six Months ended April 30, 2025" and contains management’s narrative explanation of interim financial results, business trends, liquidity, and outlook. It is not the full interim financial statements but the MD&A commentary section often filed alongside condensed interim reports. This matches the definition of a Management Report (MDA).
2025-06-18 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Financial Statements' for Genix Pharmaceuticals Corporation for the six-month period ended April 30, 2025. It contains comprehensive financial statements including the Statement of Financial Position, Statement of Comprehensive Loss, Statement of Cash Flows, and Statement of Changes in Equity, along with detailed explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H2 2025
2025-06-18 English
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Notice of Annual General Meeting and accompanying management information circular (proxy materials) for Highlander Silver Corp’s annual general meeting, including solicitation of proxies, meeting agenda items, record dates, notice-and-access procedures, and voting instructions. These materials are distributed to shareholders to provide information and solicit votes for the meeting, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2025-05-03 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form of Proxy soliciting shareholder votes for an Annual General & Special Meeting, providing voting instructions, appointment of proxyholders, and related resolutions. This is part of proxy solicitation materials sent to shareholders to request votes, which falls under Proxy Solicitation & Information Statement (PSI).
2025-05-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.